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Abstract
The success of adoptive T-cell therapies for the treatment of cancer patients depends on transferred T-
lymphocytes ﬁnding and inﬁltrating cancerous tissues. For intravenously transferred T-cells, this means
leaving the bloodstream (extravasation) from tumour blood vessels. In inﬂamed tissues, a key event in
extravasation is the capture, rolling and arrest of T-cells inside blood vessels which precedes transmigration
across the vessel wall and entry into tissues. This depends on co-ordinated signalling of selectins, integrins
and chemokine receptors on T-cells by their respective ligands which are up-regulated on inﬂamed blood
vessels. Clinical data and experimental studies in mice suggest that tumour blood vessels are anergic
to inﬂammatory stimuli and the recruitment of cytotoxic CD8+ T-lymphocytes is not very efﬁcient.
Interestingly, and somewhat counter-intuitively, anti-angiogenic therapy can promote CD8+ T-cell
inﬁltration of tumours and increase the efﬁcacy of adoptive CD8+ T-cell therapy. Rather than inhibit
tumour angiogenesis, anti-angiogenic therapy ‘normalizes’ (matures) tumour blood vessels by promoting
pericyte recruitment, increasing tumour blood vessel perfusion and sensitizing tumour blood vessels to
inﬂammatory stimuli. A number of different approaches are currently being explored to increase recruitment
by manipulating the expression of homing-associated molecules on T-cells and tumour blood vessels. Future
studies should address whether these approaches improve the efﬁcacy of adoptive T-cell therapies for solid,
vascularized cancers in patients.
Introduction
Retrospective studies of resected primary tumours from
colorectal cancer patients were the first to show that the
presence and location of tumour-infiltrating T-lymphocytes
are prognostic for patient outcome [1]. Specifically, high
densities of cytotoxic and memory T-cells within the tumour
and at the invasive tumour margin correlate with longer
disease-free survival and overall patient survival. These
findings have been extended to many cancers including
melanoma, breast, head and neck, gastric and lung [2].
How cytotoxic and memory T-cells home to and infiltrate
cancerous tissues are not understood. Blood vessels which
are especially adapted to recruit lymphocytes from the
bloodstream into lymph nodes, so-called high endothelial
venules (HEV), have been reported in solid cancers [3,4].
Further, the presence of HEV blood vessels in resected,
primary breast cancer and melanoma correlate with improved
patient outcome. Although it is not known if tumour induced
HEV are the entry portal for cytotoxic and memory T-
cells, these findings highlight the critical role that tumour
Key words: chemokine receptors, endothelial cell anergy, extravasation, high endothelial
venules, homing, integrins, selectins, tumour blood vessels, tumouricidal T-lymphocytes, vessel
normalization.
Abbreviations: ACT, adoptive cell therapy; CAR, chimaeric antibody receptor; CTL, cytotoxic T-
lymphocyte; EC, endothelial cells; HEV, high endothelial venule; ICAM-1, intercellular adhesion
molecule-1; LPS, lipopolysaccharide; LT, lymphotoxin; NK, natural killer; PNAd, peripheral node
addressin; TCR, T cell receptor; TIL, tumour inﬁltrating lymphocyte; TNF-α, tumour necrosis
factor-α.
1 To whom correspondence should be addressed (email agera@cardiff.ac.uk).
blood vessels play in orchestrating an effective immune
response by recruiting T-cells from the bloodstream into
cancerous tissues. A major goal of cancer immunotherapy is
to generate tumouricidal T-cells that are able to overcome
tumour-induced immunosuppression and kill cancer cells.
An equally important goal of cancer immunotherapy will
be to match homing addresses on tumouricidal T-cells with
vascular addresses on tumour blood vessels in order to recruit
blood-borne T-cells into cancerous tissues.
The advent of adoptive T-cell therapies to
treat cancer patients
Tumour-specific T-cells isolated from cancer patients re-
cognize and kill tumours in vitro yet the same cells
fail to eradicate cancer in the patient due to tumour-
induced immunosuppression. Early attempts to overcome
immunosuppression included isolating tumour infiltrating
lymphocytes (TILs) from resected melanoma lesions, ex-
panding tumour-reactive T-cells and infusing large numbers
back to patients with progressive metastatic melanoma [5].
These ground-breaking clinical studies have resulted in
objective tumour regression in >50 % of patients and were
the first to demonstrate that adoptive cell therapy (ACT)
using tumouricidal T-lymphocytes could be used to treat
cancer patients. Autologous T-cells used for ACT have been
extended to peripheral blood T-cells genetically modified to
express MHC-restricted, high affinity tumour-specific TCR
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Figure 1 A designer adoptive T-cell therapy for solid cancers
T-lymphocytes expressing conventional TCRs (TILs, TCRgm) or CARs at different stages of activation and differentiation are
required to kill primary and metastatic cancers and to persist in cancer patients. Fully activated, tumouricidal T-cells expressing
inﬂammation-associated homing molecules migrate from tumour blood vessels into primary cancers and sites of metastases
(including sentinel lymph nodes) where they kill cancer cells. Tumouricidal T-cells migrating to non-cancerous tissues are
unable to exert anti-cancer activity and are ineffective. Central memory T-cells expressing conventional TCRs, but not CARs,
are re-activated by endogenously processed and presented tumour-derived antigens in tumour-draining lymph nodes before
being redistributed to cancerous tissue. Central memory T-cells receive survival signals during normal recirculation through
lymphoid organs. Recruitment of T-cells into non-inﬂamed cancers is promoted by patient conditioning which sensitizes the
normally anergic tumour blood vessels to inﬂammatory mediators, increases the expression of homing-associated molecules
and promotes recruitment of tumouricidal T-cells. Maturation of tumour blood vessels by activated T-cells in already inﬂamed
tumours, promotes the development of HEV which recruit central memory T-cells into the tumour and shift the site of
T-cell activation to cancerous tissues which avoids the loss of tumouricidal T-cells to non-cancerous tissues during their
redistribution from the normal LN site of priming. γ -chain cytokines generate central memory and effector T-cells during
T-cell expansion prior to adoptive transfer to cancer patients.
(TCRgm) to overcome dominant immunosuppression in the
cancer patient [6]. The recent remarkable clinical progress
using re-directed T-cells expressing a non-MHC restricted
chimaeric antibody receptor (CAR) that binds to CD19
on B-cells for the treatment of patients with, otherwise
refractory, B-cell malignancies has highlighted the potential
of CAR T-cells to treat a wide range of solid cancers [7–
9]. However, there are inherent and perceived difficulties
in using CAR T-cells to target solid cancers, particularly
the identification of target antigens that are selectively
expressed by cancers and not normal tissues. The ability of
CAR T-cells to overcome counter-attack by the tumour as
well as local immununosuppression are also important (see
Watson et al. SHP-1; the next checkpoint target for cancer
immunotherapy? in this issue). Of equal importance is the
ability of CAR T-cells to home to and infiltrate cancerous
tissues which is the subject of this review. Objective tumour
regression of metastatic melanoma using autologous T-cells
implies that transferred T-cells homed to the cancer, but this
therapy does not work in all patients. It will be important
to determine how T-cell homing to solid cancers is linked
to the outcome of ACT if this type of immunotherapy is
to move beyond patient-based early clinical trials and into
clinical practice.
Designer adoptive T-cell therapy for solid
cancers
An ideal adoptive T-cell therapy is that tumouricidal T-
cells (CAR, TIL or TCRgm) injected into the bloodstream
are recruited into cancerous tissues to bring about cancer
cell killing (Figure 1). An additional requirement is that
transferred T-cells home to lymph nodes where survival
signals promote long-term persistence. Homing to sentinel
lymph nodes is necessary to kill lymph node metastases and
may be critical to re-stimulate effector function in TIL
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Figure 2 Homing addresses for T-cell entry into normal and cancerous tissues
T-lymphocyte recruitment from the bloodstream into tissues is regulated by a co-ordinated sequence of adhesive interactions
which can be separated into distinct stages. The term ‘homing address’ (red box) describes the combination of rolling,
activation and arrest receptors on T-cells and their respective ligands on the apical (inner) surface of blood vessel EC. Distinct
homing addresses for T-cells according to the stage of T-cell activation, nature of the inﬂammatory stimulus and the organ
involved have been identiﬁed and are listed. For example, the homing address on naı¨ve and central memory T-cells for
lymph nodes is L-selectin-CCR7-LFA-1 integrin. Speciﬁcally, L-selectin (CD62L) on T-cells binds to PNAd on the apical, inner
surface of HEV blood vessels and allows T-cells to roll on the inner blood surface in the direction of blood ﬂow. Rolling
T-cells encounter immobilized CCL21 on the EC surface which engages CCR7 on T-cells and arrests rolling T-lymphocytes
by activating LFA-1 integrin binding to ICAM-1. Activated Th1 CD4 T-cells entering inﬂamed tissues such as hypersensitivity
lesions in the skin use a different homing address. Here the rolling receptor is E-selectin which is up-regulated on vascular
EC by inﬂammatory cytokines. Inﬂammatory chemokines synthesized by inﬂamed tissues are reverse transcytosed across
the blood vessel wall and immobilized on the apical surface of EC where they arrest rolling T-cells via LFA-1 and/or VLA4
integrins. Tumour blood vessels express homing-associated adhesion molecules and chemokines typical of inﬂamed tissues
and lymph nodes and those which have been shown to regulate the recruitment of adoptively transferred tumouricidal
T-cells from tumour blood vessels into tumours in syngeneic mice are cited.
and TCRgm T-cells by endogenously processed and presented
tumour-derived antigens, but not for CAR T-cells which
bind to native cell surface antigens. One way of achieving
dual homing to cancerous tissues and lymph nodes is exploit
the fact that T-cells at different stages of activation home to
different types of tissues.
Naive and central memory T-lymphocytes continuously
recirculate through lymph nodes via HEV and lymphatics
where they screen dendritic cells for antigenic peptides
[10,11]. Following engagement of TCR and the induction
of proliferation, activated lymphocytes re-gain access to
the bloodstream and migrate to non-lymphoid tissues,
particularly sites of inflammation (Figure 2). However,
activated CD4+ T-cells also localize to non-lymphoid tissues
such as the lungs, liver, gut and salivary glands in the
absence of ongoing inflammation [12,13]. Following primary
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infection with virus or bacteria, activated CD8+ T-cells are
found at sites of virus replication where effector T-cells
differentiate into tissue resident memory cells and play a
key role in protection against re-infection [14]. Activated
CD8+ T-cells also migrate to non-lymphoid organs such
as the liver, lungs, lamina propria, fatpad, peritoneal cavity
and in some cases, the CNS even though they were not the
primary sites of virus replication in these studies [15,16].
If the homing properties of pathogen-specific effector T-
cells can be reproduced in CAR or TCRgm T-cells, their
widespread dissemination following adoptive transfer into
the bloodstream would be an advantage to target primary as
well as metastatic disease. Lymph node homing properties
to promote persistence of transferred T-cells will depend on
limiting T-cell differentiation during in vitro expansion to
maintain a central memory phenotype [17]. Naive and self-
renewing T-cells generated from autologous haemopoietic or
induced pluripotential stem cells provide additional sources
of T-cells for adoptive T-cell therapy which offer superior
efficacy due to their ability to recirculate through lymphoid
organs.
Homing addresses for T-lymphocyte
recruitment from the bloodstream into
tissues
Recruitment from the bloodstream into tissues involves a
sequence of adhesive interactions between T-lymphocytes
and cells of the blood vessel wall which can be divided
into distinct stages of rolling, activation-induced arrest and
movement into tissues (Figure 2). It is a rapid process taking
up to 10 min to complete and the ability to image the
behaviour of T-cells during rolling and activation-induced
arrest inside small blood vessels has allowed the adhesion
molecules and signalling events that regulate these stages to be
identified. The subsequent movement of T-cells into the tissue
parenchyma is regulated independently of activated-induced
arrest inside blood vessels. For example, T-lymphocytes
accumulate in the walls and perivascular sheath of blood
vessels (so-called perivascular cuffing) when entry into the
tissue parenchyma is prevented [18,19].
A key event in T-cell homing is the selection of T-
lymphocytes from the total pool of circulating leucocytes
on to the vessel wall under the shear stresses generated
by flowing blood. This occurs primarily in post-capillary
venules where haemodynamic forces promote margination
of leucocytes to the outside stream of flowing blood. The
term ‘homing address’ describes the combination of rolling,
activation and arrest receptors on T-cells and their respective
ligands or ‘vascular address’ expressed on the apical (inner)
surface of blood vessel endothelial cells (EC) that directs
entry into tissues. Homing addresses for lymph nodes and
sites of inflammation in the skin and other organs have
been identified (Figure 2). The considerable heterogeneity in
vascular endothelium between organs, at different locations
in the vascular bed and in T-cell subsets means that there are
distinct homing addresses for T-cells according to the stage of
T-cell activation, nature of the inflammatory stimulus and the
organ involved [10]. Although the general rule is that homing
addresses on T-cells comprise a selectin–chemokine receptor–
integrin combination, there are exceptions (Figure 2). One
important exception is that TCR recognition of peptide–
MHC complexes on the inside walls of blood vessels can
substitute for chemokine receptors and induce integrin-
dependent arrest of rolling T-cells [20]. Antigen can be
presented either by perivascular dendritic cells, which extend
protrusions into the vessel lumen [20], or by EC [21].
Following the recruitment of T-cells expressing cognate TCR,
the release of inflammatory cytokines activates local blood
vessels which recruit non-cognate TCR (so called 3rd party
or bystander T-cells) in a chemokine-dependent manner using
a conventional selectin–chemokine receptor–integrin homing
address [20].
Some of the adhesion molecules and chemokines that
regulate T-lymphocyte homing into sites of inflammation
and/or lymph nodes have been implicated in homing
to cancers in experimental mice [22–25]. Knowledge of
selectin, integrin and chemokine receptors expressed by
infiltrating cytotoxic T-lymphocytes and their respective
ligands in cancerous and normal tissues will assist in the
selection of appropriate cancer homing addresses for
expression in CAR or TCRgm T-cells. For example,
transduction of CAR T-cells with chemokine receptors for
human tumour cell-derived chemokines increases homing to
solid cancers and controls their growth in immunodeficient
mice [26,27].
Lessons about T-lymphocyte homing from
experimental animal models and early
phase clinical studies of adoptive T-cell
therapies to treat solid cancers
Early studies of leucocyte (neutrophil) behaviour inside
blood vessels of subcutaneous tumours in immunodeficient
mice demonstrated lower levels of rolling and arrest than in
normal skin, even after administration of tumour necrosis
factor-α (TNF-α) or LPS, which suggested that tumour
blood vessels are anergic to inflammatory stimuli [28,29].
Subsequent studies demonstrated clearly that effector CD8+
T-lymphocytes do not spontaneously roll or undergo
activation induced arrest in tumour blood vessels even
following LPS administration [22]. The fact that tumour
blood vessels are poor at recruiting CTLs has suggested that
they represent a vascular checkpoint which limits the success
of ACT, as well as other immunotherapies such as vaccination
and checkpoint inhibition [22,30]. A number of different
mechanisms underlie poor CTL recruitment, not least of
which is that tumour blood vessels are highly disorganized,
immature, lacking an organized pericytic sheath and poorly
perfused (Figure 3). Low CD8+ T-cell flux through
tumour blood vessels, absence of shear stresses necessary
for recruitment and/or inefficient chemokine presentation
could all contribute to poor CTL recruitment. Additional
mechanisms include tumour-derived products which restrict
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence
4.0 (CC BY).
Chimeric antigen receptor therapy in haematology and oncology: current successes and challenges 381
Figure 3 T-cell recruitment from normal, inﬂamed and tumour blood vessels
(Left) In normal or inﬂamed tissues, the vascular network is highly ordered and T-cells are recruited from post-capillary
venules where haemodynamic forces promote the margination of T-cells and other leucocytes to the outside stream of
ﬂowing blood. T-cell recruitment from HEV in lymph nodes or inﬂamed blood vessels in non-lymphoid tissues follows the
multistep adhesion cascade described in Figure 2. Inset shows T-cell (green) binding to and in the process of transmigrating
the EC lining and surrounding pericytic sheath which together comprise the blood vessel wall. (Right) Angiogenic blood
vessels growing inside the tumour in response to hypoxia lack pericyte support and are highly disorganized, poorly perfused
and leaky. They are non-responsive (anergic) to inﬂammatory stimuli but responsive to tumour-derived factors that prevent
expression of homing molecules on tumour EC and induce FasL expression which directly kills tumouricidal T-cells. As a
consequence intra-tumoural blood vessels are poor at recruiting effector CD8+ T-cells into the tumour [30]. In contrast,
peritumoural blood vessels respond to inﬂammatory stimuli, up-regulate homing-associated molecules and recruit effector
CD8+ T-cells to the peritumoural area. Cognate recognition of tumour antigen by conventional TCR regulates the movement
of extravasated T-cells into the tumour to kill cancer cells. Insets show (left) immature, anergic tumour blood vessel lacking
pericyte support inside the tumour and (right) mature peritumoural vessel supporting T-cell recruitment adjacent to a
ﬁbroblast-associated matrix which T-cells cross to enter the tumour. Chemokine production by cancer-associated ﬁbroblasts
can limit tumouricidal T-cell entry and killing of tumour tissue by arresting T-cells in the peritumoural area [30].
expression of homing molecules, such as ICAM-1, on tumour
EC [31] and induce expression of FasL [32]. EC anergy may
be related to the pro-angiogenic tumour environment since
angiogenic growth factors prevent cytokine induced homing
molecule expression by EC [33].
Adoptive T-cell therapy does restrict the growth of
solid vascularized cancers in experimental mice and in
patients so, if tumour blood vessels are poor at recruiting
injected T-cells, how does it work? Intravital imaging has
demonstrated that tumour specific T-cells are recruited,
not from blood vessels within the tumour nest but, from
blood vessels in the peritumoural area where homing-
associated adhesion molecules are preferentially expressed
[34] (Figure 3). Recruitment from blood vessels is not
dependent on TCR recognition of cognate tumour antigen
and, most likely, reflects the local inflammatory environment
which is not restrained by the adjacent tumour environment.
However, the motility of CTLs and their ability to infiltrate
the tumour mass does depend on cognate recognition of
tumour antigen by TCR [35,36]. The density of infiltrating
cytotoxic and memory T-cells at the invasive tumour margin
as well as within the tumour of cancer patients correlate
with overall patient survival [2]. Preclinical studies showing
that T-cells exit peritumoural blood vessels before invading
tumour tissue support the clinical observations. However,
whether T-cells are recruited directly into the tumour nest
or indirectly from the peritumoural area may depend on the
location and size of the tumour. The efficacy of CAR or
TCRgm T-cell therapy for solid tumours is cell dose dependent
[37,38] so understanding what controls the number of
tumouricidal T-cells that accumulates inside tumour tissues
is important because this correlates with patient survival. If
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MHC-restricted TCR signalling is required for T-cell
infiltration of cancerous tissues, it will be important to
determine whether signalling pathways downstream of CARs
substitute for TCR signalling or whether there is an
obligatory role for the canonical TCR in this process. The
fact that CAR expressing human T-cells migrate to and
control the growth of human tumours in immunodeficient
mice does not provide an answer to the important question
of whether CARs can fully substitute for a conventional TCR
in T-cell homing since xenoreactivity as well as alloreactivity
(if T-cell and tumours are not MHC-matched) could regulate
T-cell infiltration of tumours in these mouse models. The
preclinical studies on T-cell homing to cancerous tissues
described above have used transplanted antigen-expressing
tumours and high numbers of transgenic T-cells specific
for transfected antigens. Therefore, analysis of spontaneous
mouse tumours relevant to human cancers using CARs and
TCRgm T-cells recognizing relevant tumour antigens will be
required before applying the rules governing tumouricidal T-
cell homing in transplanted syngeneic or xenogeneic tumours
to human cancers.
There have been very few clinical studies of T-cells
following injection into the venous circulation of cancer
patients. However, an early study showed that 111indium-
labelled TILs homed to melanoma lesions and TIL homing
was associated with objective clinical responses in 38 %
(10/26) patients [39]. In a phase I study of CAR T-cells in
ovarian cancer, accumulation of CAR T-cells in a pelvic mass
(presumed cancer) was seen in a single patient out of the seven
treated but there were no clinical responses in any patient
[40]. These results raise the possibility that the lack of clinical
response is related to lack of T-cell homing to the cancer.
Studies in mice have shown that HEV expression of the arrest
chemokine, CCL21, is down-regulated in tumour-draining
(sentinel) lymph nodes and T-lymphocyte recruitment is
consequently reduced [41], which, in cancer patients, will
affect T-cell re-stimulation and survival. Whole body imaging
showed that CAR T-cells localized in the lungs and then
the liver and spleen in 7/7 patients. Interestingly, lung
localization persisted for longer when re-stimulated T-cells
were transferred [40]. In experimental mice, tumour-specific
CD8+ T-cells traffic indiscriminately to lymph nodes, liver,
spleen and lungs in tumour-bearing mice while still being able
to control tumour growth [42]. This finding suggests that the
ability of transferred T-cells to home to cancerous tissues may
not be limited by widespread distribution to non-cancerous
tissues, which has been the conclusion thus far.
Indiscriminate homing of CAR T-cells, TILs and TCRgm
may, however, contribute to their lack of persistence which
has been repeatedly reported in patients and experimental
mouse models. This may be due to lack of encounter
with cognate antigen following homing to non-cancerous
tissues and/or lack of homing to lymph nodes where
survival and/or reactivation signals are presented. Inclusion
of CD28 or other co-stimulator signalling domains in so-
called second and third generation CARs prolongs the
persistence of CAR T-cells but whether this is related to
lymph node homing remains to be determined. Checkpoint
blockade inhibitors and host-conditioning using fludarabine
and cyclophosphamide increase the efficacy of TILs, CAR
and TCRgm T-cells but whether this is related to altered
homing is also not known [8,43–45]. However, strategies to
boost the efficacy of CAR T-cells will need to be weighed
against the risks of clonal deletion or lymphoma development
and increased incidence of unrelated cancers [46].
Overcoming vascular checkpoints in
tumours: inducing blood vessel
normalization and the neogenesis of HEV
It is over 40 years since Judah Folkman first proposed that
tumour growth could be restricted by blocking the growth
of blood vessels that supply the tumour [47]. Since that time
intense research activity has identified vascular endothelial
growth factor (VEGF) as a primary angiogenic stimulus
which is produced by tumour cells in response to hypoxia.
There has been a growing realization that hypoxia also
fuels the immunosuppressive tumour microenvironment, in
part due to accumulation of immunosuppressive leucocytes
such as Foxp3+ regulatory T-cells (Tregs) [48]. The use
of different anti-angiogenic therapies has revealed that,
instead of preventing blood vessel growth, sub-optimal doses
‘normalize’ or mature tumour blood vessels by promoting
pericyte recruitment and increasing vessel perfusion which
may improve oxygenation and remove suppressive meta-
bolites from the tumour microenvironment [49]. Vascular
normalization is associated with a reversal of EC anergy,
increased effector T-cell infiltration and control of tumour
growth in both autochthonous and transplanted cancers,
establishing a robust link between vascular normalization and
improved T-cell-dependent anti-cancer immunity [50,51].
Tregs suppress blood vessel normalization [52] but a range of
inflammatory stimuli including tumour EC-targeted TNF-α
[53,54], eosinophils [55], irradiation [56] and TLR ligands
[57], in the presence or absence of transferred tumour
specific T-cells, can overcome Treg suppression and induce
vessel normalization and homing molecule expression on
tumour EC. Hyperthermia induced IL-6 trans-signalling and
blockade of endothelin B receptor in tumour EC also up-
regulate ICAM-1 expression and promote CTL recruitment
[22,32]. There is a growing realization that chemotherapy
induces immune-mediated destruction of cancer cells but
whether tumour blood vessel normalization is involved
remains to be determined.
An exquisite example of tumour blood vessel maturation
is the development (neogensis) of specialized HEV blood
vessels. Studies in mice suggest that, similar to tumour
blood vessel normalization, HEV neogenesis is regulated by
type 1 inflammation [25] and can be restrained by Tregs
[58]. In marked contrast with HEV development in lymph
nodes which depends on dendritic cell expressed LTαβ
engagement of LTβR in EC, HEV neogenesis in mouse
tumours is driven by CD8+ T- and/or NK cell secretion
of LTα3 and IFN-γ which induce expression of peripheral
node addressin (PNAd, a ligand for L-selectin) and the arrest
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chemokine CCL21 respectively. Although comprising<10 %
of the tumour vascular network, newly formed HEV in
mice recruit adoptively transferred naı¨ve T-cells directly from
the bloodstream into the tumour where cross-presenting
APC activate naı¨ve T-cells to kill tumour tissue [25]. The
development of HEV establishes a site of T-cell priming
and re-activation inside cancerous tissues and avoids the
loss of tumouricidal T-cells to non-cancerous tissues during
redistribution from the normal site of priming in lymph nodes
[59]. Interestingly, expression of the HEV-specific marker,
PNAd, is below the level of detection using conventional
immunohistochemical staining in some tumours and EC
lining HEV expressing low levels of PNAd are flat [25],
as opposed to the characteristic, LTβR-dependent cuboidal
morphology of HEV in LNs [60] which suggests that they
are not fully differentiated. The extent and role of HEV
development in clinical cancers warrant further investigation
as a potential entry site for central memory CAR and TCRgm
T-cells which are predicted to have superior efficacy in
adoptive cell therapies.
Summary, outstanding issues and future
directions
Although the promise of CAR T-cell therapy for the
treatment of solid cancers has yet to be realized, it is
clear that adoptive immunotherapy using T-cells expressing
conventional TCRs does not work for all patients. Inefficient
recruitment by immature tumour blood vessels and lack of
persistence of injected T-cells are important determinants
of successful outcomes in experimental mice. Manipulating
homing addresses on T-cells and vascular addresses on
tumour blood vessels to facilitate the recruitment of tumour-
specific T-cells offer a combined approach to overcome these
limitations in cancer patients. However, longitudinal imaging
of transferred T-cells using non-invasive imaging using
PET/SPECT tracers will be required to determine whether
homing and persistence of transferred T-cells correlate with
therapeutic outcomes.
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